Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
20171.5k citationsSimon D Harding, Joanna L Sharman et al.profile →
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
2008954 citationsSauveur-Michel Maira, Frédéric Stauffer et al.Molecular Cancer Therapeuticsprofile →
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
2015933 citationsChristopher Southan, Joanna L Sharman et al.profile →
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes
2017572 citationsS P H Alexander, Doriano Fabbro et al.British Journal of Pharmacologyprofile →
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes
2015562 citationsS P H Alexander, Doriano Fabbro et al.British Journal of Pharmacologyprofile →
Trends in kinase drug discovery: targets, indications and inhibitor design
Countries citing papers authored by Doriano Fabbro
Since
Specialization
Citations
This map shows the geographic impact of Doriano Fabbro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doriano Fabbro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doriano Fabbro more than expected).
This network shows the impact of papers produced by Doriano Fabbro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doriano Fabbro. The network helps show where Doriano Fabbro may publish in the future.
Co-authorship network of co-authors of Doriano Fabbro
This figure shows the co-authorship network connecting the top 25 collaborators of Doriano Fabbro.
A scholar is included among the top collaborators of Doriano Fabbro based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Doriano Fabbro. Doriano Fabbro is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Alexander, S P H, Eamonn Kelly, Alistair Mathie, et al.. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. British Journal of Pharmacology. 176(S1). S1–S20.397 indexed citations breakdown →
Alexander, S P H, Doriano Fabbro, Eamonn Kelly, et al.. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology. 176(S1). S297–S396.485 indexed citations breakdown →
Maira, Sauveur-Michel, Frédéric Stauffer, Josef Brueggen, et al.. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics. 7(7). 1851–1863.954 indexed citations breakdown →
Manley, Paul W., Josef Brüggen, Doriano Fabbro, Georg Martiny‐Baron, & Thomas Meyer. (2007). Extended kinase profiling of the Bcr-Abl inhibitor nilotinib. Cancer Research. 67. 3249–3249.9 indexed citations
12.
Roesel, Johannes, Guido Bold, Josef Brueggen, et al.. (2005). Pharmacological profile of the FLT3-Tyrosine Kinase Inhibitor AST487. Cancer Research. 65. 1409–1409.1 indexed citations
13.
Manley, Paul W., Jürgen Mestan, Sandra W. Cowan‐Jacob, et al.. (2005). AMN107: Inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase. Cancer Research. 65. 1408–1408.2 indexed citations
Manley, Paul W., Juergen Mestan, Thomas Meyer, & Doriano Fabbro. (2004). An ELISA for PDGFR phosphorylation: Comparison of effects of STI571 on cellular Bcr-Abl, c-Kit and PDGFR-β protein kinases. Cancer Research. 64. 345–346.1 indexed citations
17.
Lansiaux, Amélie, Doriano Fabbro, Thomas Meyer, François Hamy, & Christian Bailly. (1999). Le PKC 412. Bulletin du Cancer. 86(7). 614–617.1 indexed citations
Marte, Barbara, Diana Graus-Porta, Marc G. Jeschke, et al.. (1995). NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells.. PubMed. 10(1). 167–75.91 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.